Back to top

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a ...

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases | GLUE Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Monte Rosa Therapeutics, Inc. (GLUE)